Congratulations to Dr. Erica Mayer ⁦Erica Mayer⁩ for the Dana-Farber Innovation Award, recognizing her commitment to clinical care and research. Wonderful acceptance speech acknowledging contributions of NP, PA, research RN, and research staff. ⁦⁦Dana-Farber’s Breast Oncology Center⁩

We are so proud of ⁦Douglas Drachman⁩ chairing #ACC24 and kicking off the annual meeting this morning. Congratulations on a tremendous job so well done!! 🎉🎉

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for hormone receptor-positive/HER2- #MetastaticBreastCancer Erica Mayer
Just published Journal of Clinical Oncology🔽
pubmed.ncbi.nlm.nih.gov/38513188/

Adding palbociclib to fulvestrant did not improve PFS in the PACE randomized phase 2 trial - Paolo Tarantino
Erica Mayer Sara Tolaney
oncodaily.com/41842.html

#Cancer #DanaFarberCancerInstitute #OncoDaily #Oncology

Out in JCO, the PACE randomized phase 2 trial by Erica Mayer Sara Tolaney et al. Among pts with HR+ MBC and prior progression on CDK4/6i (90% palbo), adding palbo to fulvestrant did not improve PFS (4.6 vs 4.8 mo). Interesting signal with fulv/palbo/avelumab. ascopubs.org/doi/10.1200/JC…

Fantastic leadership Charu Aggarwal, MD, MPH, FASCO and a wonderful communications team; will be a terrific press program at #ASCO24 !

Dana-Farber’s Breast Oncology Center is leading a trial on the use of #ColdCaps in preventing hair loss with novel #BreastCancer therapies, including sacituzumab, eribulin, or trastuzumab deruxtecan. Contact us for info about the study or visit: dana-farber.org/breast-oncolog…… #ScalpCooling ; PI Elahe Salehi DNP

On #RareDiseaseDay , let's highlight male breast cancer and ongoing efforts like the #ETHANstudy . Let's support research, spread awareness, and strive for better treatments for #MaleBreastCancer .

Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium are leading the #ETHANstudy , which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer .
For more information call 877-338-7425 or visit:
dana-farber.org/clinical-trial…

We are leading a phase 2 trial, called #TRADE , to assess if a brief dose escalation of adjuvant #abemaciclib w/ ongoing endocrine therapy reduces side effects & improves tolerability in patients with early-stage HR-positive and HER2-negative #BreastCancer .
dana-farber.org/clinical-trial…

CDK Study by ASCO in the news: ASCO launches 500-patient study to test dosing strategy of 2 drugs for breast cancer. Starting treatment at full dose then lowering the dose for side effects vs starting with a lower dose and increasing if patient does well. apnews.com/article/cancer…

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer (Webinar Video Proceedings) | Research To Practice ⁦Erica Mayer⁩ #bcsm m.researchtopractice.com/YiR2023/HRPosB…

Check out the new Dana-Farber Insights blog featuring Rachel Freedman, MD, MPH and Erica Mayer discussing new strategies in correcting historical trends and disparities in cancer care and prevention #BreastCancerResearch #bcsm #clinicalresearch
👉 dana-farber.org/newsroom/featu…

Dana-Farber’s Breast Oncology Center is leading a phase II study of niraparib with dostarlimab therapy as neoadjuvant treatment for patients with BRCA-mutated #BreastCancer .
For more information call 877-338-7425 or visit: dana-farber.org/clinical-trial…

This week, @ericabmayer is our guest as part of our 'on-the-road' mini-series. We dive deep into her oncological experience in the breast cancer world, working at Dana-Farber & Harvard Medical School. #MedTwitter #Cancer #Cancer Research

open.spotify.com/episode/2aSe2f…

We are leading a randomized Phase 2 trial for stage 1 HER2+ #BreastCancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (ATEMPT 2.0).
For more information call 877-338-7425 or visit:
dana-farber.org/clinical-trial… Sara Tolaney

#MaleBreastCancer accounts for 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer. blog.dana-farber.org/insight/2024/0…

Jose Pablo Leone, MD, Director of the Program for #BreastCancer in Men, and Erica Mayer, MD, MPH, Director of Breast Cancer Clinical Research discuss the #ETHANstudy , which aims to improve treatment for #MaleBreastCancer . Leran more here⬇️
blog.dana-farber.org/insight/2024/0…
Erica Mayer

Dana-Farber’s Breast Oncology Center is leading the #ADEPT study, examining the non-chemotherapy combination of HER2-directed therapy (trastuzumab and pertuzumab) + hormonal therapy as a treatment after surgery for early HR+/HER2+ #BreastCancer .
Call 877-338-7425 or visit:
dana-farber.org/clinical-trial…

For #trialtuesday , #CCTI_DFCI presents trial 23-044. STX-478 mutant-selective, PI3Kα small molecule inhibitor, highly selective for kinase domain mutations that comprise over 40% of all PI3Kα mutations in breast cancers. Dana-Farber Dana-FarberNews
Visit:forms.office.com/r/kM7e6JVxre